Gorka San JosÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/420341/publications.pdf

Version: 2024-02-01

		159358	253896
46	3,190	30	43
papers	citations	h-index	g-index

47	47	47	4306
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nature Reviews Cardiology, 2021, 18, 479-498.	6.1	128
2	Reprint of â€œThe complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linkingâ€• Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118521.	1.9	7
3	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia, 2020, 40, 223-236.	0.2	21
4	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. Circulation, 2020, 141, 751-767.	1.6	48
5	The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 1421-1432.	1.9	50
6	The renal immune-inflammatory component of arterial hypertension: emerging therapeutic strategies. Cardiovascular Research, 2019, 115, 696-698.	1.8	2
7	Myocardial Remodeling in Hypertension. Hypertension, 2018, 72, 549-558.	1.3	123
8	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. Scientific Reports, 2017, 7, 41865.	1.6	21
9	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. Scientific Reports, 2017, 7, 40696.	1.6	39
10	Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men. Free Radical Research, 2017, 51, 389-396.	1.5	18
11	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. Journal of Hypertension, 2017, 35, 853-861.	0.3	58
12	The Hypertensive Myocardium. Medical Clinics of North America, 2017, 101, 43-52.	1.1	21
13	Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients. Journal of Hypertension, 2016, 34, 130-138.	0.3	30
14	Myocardial Collagen Cross-Linking IsÂAssociated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. Journal of the American College of Cardiology, 2016, 67, 251-260.	1.2	127
15	Circulating Biomarkers of Myocardial Fibrosis. Journal of the American College of Cardiology, 2015, 65, 2449-2456.	1.2	196
16	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-Î²1 up-regulation. Clinical Science, 2014, 126, 497-506.	1.8	80
17	Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease. Hypertension, 2014, 63, 468-474.	1.3	16
18	A Synthetic Peptide from Transforming Growth Factor-Î²₁Type III Receptor Inhibits NADPH Oxidase and Prevents Oxidative Stress in the Kidney of Spontaneously Hypertensive Rats. Antioxidants and Redox Signaling, 2013, 19, 1607-1618.	2.5	21

#	Article	IF	Citations
19	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. Clinical Science, 2013, 125, 291-300.	1.8	14
20	A 28-kDa Splice Variant of NADPH Oxidase-4 Is Nuclear-Localized and Involved in Redox Signaling in Vascular Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, e104-12.	1.1	71
21	Contrasting Regulation of NOX4 versus NOX2 in Patients with Aortic Stenosis. Free Radical Biology and Medicine, 2011, 51, S46.	1.3	0
22	HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. Cardiovascular Research, 2011, 92, 247-255.	1.8	42
23	The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes. Frontiers in Bioscience - Elite, 2011, E3, 1467-1474.	0.9	5
24	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. Clinical Science, 2010, 119, 185-185.	1.8	0
25	Corrigendum to â€œPreliminary characterisation of the promoter of the human p22phoxgene: Identification of a new polymorphism associated with hypertensionâ€•[FEBS Lett. 542 (2003) 27-31]. FEBS Letters, 2010, 584, 4709-4709.	1.3	0
26	Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages. Free Radical Biology and Medicine, 2009, 46, 1058-1067.	1.3	40
27	Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. Journal of Hypertension, 2009, 27, 1420-1430.	0.3	13
28	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. Clinical Science, 2009, 116, 233-240.	1.8	8
29	NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clinical Science, 2008, 114, 173-182.	1.8	90
30	Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 587-593.	1.1	82
31	A novel CYBA variant, the â€“675A/T polymorphism, is associated with essential hypertension. Journal of Hypertension, 2007, 25, 1620-1626.	0.3	34
32	Oxidative Stress, Endothelial Dysfunction and Cerebrovascular Disease. Cerebrovascular Diseases, 2007, 24, 24-29.	0.8	65
33	The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. Journal of Hypertension, 2006, 24, 1299-1306.	0.3	83
34	Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome. Diabetes, 2006, 55, 209-215.	0.3	121
35	Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidaseâ€“dependent superoxide production in patients with early chronic kidney disease. Kidney International, 2005, 68, S71-S75.	2.6	45
36	Oxidative stress and vascular remodelling. Experimental Physiology, 2005, 90, 457-462.	0.9	129

#	Article	IF	Citations
37	NADPH Oxidaseâ€“Dependent Superoxide Production Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Atherosclerotic Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1452-1457.	1.1	62
38	NADPH Oxidase-Mediated Oxidative Stress: Genetic Studies of thep22phoxGene in Hypertension. Antioxidants and Redox Signaling, 2005, 7, 1327-1336.	2.5	86
39	Functional Effect of the p22 phox â^'930 A/G Polymorphism on p22 phox Expression and NADPH Oxidase Activity in Hypertension. Hypertension, 2004, 44, 163-169.	1.3	89
40	Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. Journal of Hypertension, 2004, 22, 2169-2175.	0.3	92
41	Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension. FEBS Letters, 2003, 542, 27-31.	1.3	86
42	Oxidative Stress in Arterial Hypertension. Hypertension, 2001, 38, 1395-1399.	1.3	380
43	Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?. Nephrology Dialysis Transplantation, 2001, 16, 2-5.	0.4	46
44	Polymorphisms and Promoter Overactivity of the p22phoxGene in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats. Circulation Research, 2001, 88, 217-222.	2.0	61
45	Vascular oxidant stress: Molecular mechanisms and pathophysiological implications. Journal of Physiology and Biochemistry, 2000, 56, 57-64.	1.3	101
46	Vascular NADH/NADPH Oxidase Is Involved in Enhanced Superoxide Production in Spontaneously Hypertensive Rats. Hypertension, 2000, 35, 1055-1061.	1.3	339